G Medical Innovations Enters Final Phase of Commercial Approval in China

Be the First to Comment Read

G Medical Innovations Enters Final Phase of Commercial Approval in China

 G Medical Innovations Enters Final Phase of Commercial Approval in China

G Medical Innovations (ASX: GMV) updated that regulatory audits for its facility in China are scheduled to be conducted towards the end of this month and the outcome would be released in early October. The audit would bring the company a step closer to commercializing its Prizma medical smartphone case in the mainland. Once the result is out, the company would get the certification to start the manufacturing of the units. Before the audit, these units cannot be sold in the territories that require approvals of either of the respective authorities. Once the audit is complete, G Medical would be able to crank up its production capacity to the maximum in the country. [optin-monster-shortcode id="wxhmli4jjedneglg1trq"]

The company has already started rolling out its Prizma Medical device in the United States. The company’s team within GMedDx would pitch the FDA approved Prizma Medical device in the United States to primary and specialty service provider. The service providers have either the option to buy the device from G Medical and issued to the patients or patients can purchase straight from the company furnishing physician prescription. The company is penetrating in the United Kingdom market as well by appointing sales manager on the commission basis to sell Prizma and GMP devices.

The company has also talked about its intentions to list on the Hong Kong exchange. Moving ahead with the plan, GMV has finalized Global Investment Bank, UOB Kay Hian Ltd. as advisors for the IPO of its Chinese subsidiary. The medical device company suggests that it is holding early-stage discussions with various organizations and would announce an update pertaining to the same in the market.

GMV was trading at $0.355, down 6.579% (AEST: 04:00 p.m.) in today’s session and has the market capitalization of circa $129.11 Mn as on 06 September 2018.

Dividend Stocks To Buy

The Income available from dividends remains attractive for many investors.

We take a look at the best yields on the market and assess what they say about a company’s prospect.

One Thing is certain, though, Australia interest rates are still low, making income difficult to come by and keeping the focus for many investors on high yielding stocks. Kalkine’s team of analysts bought you handpicked report for “Top 25 Dividend Stocks For 2018.”

ASX-relevant Special Reports are published year-round to provide a detailed analysis into an investing opportunity or a potential risk to your portfolio.

Click here to get your free report.


The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkinemedia.com and associated websites are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.


Speak your Mind

Featured Articles

kalkine logo


Top Penny Picks under 20 Cents to Fit Your Pocket! Get Exclusive Report on Penny Stocks For FREE Now.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK